查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1370916

基因治療市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按載體類型、交付方法、適應症、地區、競爭細分

Gene Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Vector Type, By Delivery Method, By Indication, By Region, By Competition
出版日期: | 出版商: TechSci Research | 英文 190 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022年全球基因治療市場價值為60.1億美元，預計在預測期內將大幅成長，預計年複合成長率（CAGR）為9.26%，預計到2028年將達到101.3億美元。涉及透過修改、替換或補充導致疾病的缺失或有缺陷的基因組合來治療疾病。它已成為對抗退化性疾病的一個非常理想的研究前沿。

主要市場促進因素

市場概況
預測期 2024-2028
2022 年市場規模 60.1億美元
2028 年市場規模 101.3億美元
2023-2028 年年複合成長率 9.26%
成長最快的細分市場 非病毒載體
最大的市場 北美洲
  • 1.基因研究的進步：對疾病遺傳基礎的深入了解使科學家能夠找出導致各種疾病的特定基因。這些知識對於開發精確的基因療法至關重要，這些療法可以糾正或替換有缺陷的基因，解決疾病的根本原因。 CRISPR-Cas9、TALEN 和鋅指核酸酶等基因編輯技術的進步，透過實現準確、高效的基因修飾，徹底改變了基因療法。這反過來又為治療遺傳性疾病開闢了新途徑。
  • 2.遺傳性疾病盛行率上升：被診斷為遺傳性疾病的人數不斷增加，凸顯了對有效治療的醫療需求尚未得到滿足。基因療法為這些疾病提供了有針對性的、持久的解決方案，這些疾病通常是症狀治療，而不是從遺傳源頭進行治療。遺傳性疾病的日益流行擴大了潛在的患者基礎，推動了對基因治療的需求和市場機會。
  • 3.合作與夥伴關係：基因治療需要多學科方法，涉及分子生物學、遺傳學、生物技術、臨床研究和監管事務。合作有助於匯集不同領域的知識、專業知識和最佳實踐，促進創新並加速更先進基因療法的開發。合作夥伴關係提供專業技術和工具，促進基因療法開發的突破。它們還有助於開發可擴展的製造技術，並為應對複雜的監管環境提供支持，最終促進市場成長。

主要市場挑戰

  • 1.技術複雜性：有效基因療法的開發需要對遺傳學、分子生物學和複雜的細胞過程有深刻的了解。設計精確靶向和修改特定基因的療法的複雜性可能會導致研究和開發時間延長。實現精確和受控基因傳遞的挑戰以及潛在的意外後果造成了技術困難，影響了治療的成功。
  • 2.開發成本高：基因治療開發涉及大量的初始研究、大量的臨床試驗成本、監管合規費用以及建立熟練團隊的需要。尖端技術和精密的實驗室設備也導致了高昂的開發成本。由於其專業性，吸引和留住該領域的專家可能成本高昂。

主要市場趨勢

  • 1.擴大治療標靶：新治療標靶的確定擴大了基因治療的應用範圍，包括癌症、心血管疾病、神經退化性疾病和罕見疾病等複雜疾病。這種多元化吸引了更大的患者群體，透過增加商業機會來推動市場成長。它促進創新，加速研究，並帶來更多樣化的臨床試驗環境。
  • 2.不斷發展的基於CRISPR的療法：CRISPR-Cas9技術在基因編輯方面的精確性加速了基因療法的研究。其精確靶向和修改基因的能力提高了治療效果和安全性。基於 CRISPR 的療法有潛力解決從單基因到複雜病症的廣泛遺傳性疾病，並簡化法規核准流程。 CRISPR 技術的普及刺激了全球合作，導致競爭、創新和市場擴張。

細分市場洞察

載體類型見解：預計非病毒載體市場在整個預測期內將顯著成長。與病毒載體相比，非病毒載體提供了更安全的特性，並且降低了免疫反應風險。它們整合到宿主基因組的風險較低，增強了長期治療應用。非病毒載體也簡化了製造過程，有可能降低生產成本並實現可擴展性。它們的安全優勢可以帶來更順暢的監管途徑，加快審核速度。非病毒載體技術的出現吸引了眾多產業參與者，促進了競爭、創新和市場擴張。

給藥方法見解：體內細分市場因其非侵入性而佔據市場主導地位，使其更容易被患者接受並降低與外科手術相關的風險。體內基因治療可以全身進行，使其適用於更廣泛的患者，並且適用於影響多個器官或組織的疾病。其全身性作用可能有益於具有廣泛遺傳異常的疾病，並提供持久的影響。體內基因療法的多功能性吸引了各種各樣的研究人員、開發人員和公司進入基因治療市場。

區域洞察

北美，特別是美國，將在 2022 年成為基因治療市場的領導者。這歸功於該地區強大的研究和創新生態系統，吸引了來自不同來源的大量投資進入基因治療研究和臨床試驗。北美擁有完善的臨床試驗基礎設施、許多致力於基因治療的生物技術公司以及先進的醫療基礎設施，為基因治療的研究、臨床應用和採用創造了良好的環境。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：臨床試驗分析

  • 正在進行的臨床試驗
  • 已完成的臨床試驗
  • 終止的臨床試驗
  • 按開發階段分類的管道細目
  • 管道細分（按狀態）
  • 按研究類型分類的管道細目
  • 按地區分類的管道明細
  • 臨床試驗熱圖

第 5 章：客戶之聲

第 6 章：全球基因治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按載體類型（病毒載體、非病毒載體）
    • 依遞送方式（體內、體外）
    • 按適應症（罕見疾病、癌症、神經系統疾病、其他）
    • 按地區（北美、歐洲、亞太地區、南美、中東和非洲）
    • 按公司分類 (2022)
  • 市場地圖
    • 按向量類型
    • 按交貨方式
    • 按指示
    • 按地區

第 7 章：北美基因治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按載體類型（病毒載體、非病毒載體）
    • 依遞送方式（體內、體外）
    • 按適應症（罕見疾病、癌症、神經系統疾病、其他）
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 8 章：歐洲基因治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按載體類型（病毒載體、非病毒載體）
    • 依遞送方式（體內、體外）
    • 按適應症（罕見疾病、癌症、神經系統疾病、其他）
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第 9 章：亞太地區基因治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按載體類型（病毒載體、非病毒載體）
    • 依遞送方式（體內、體外）
    • 按適應症（罕見疾病、癌症、神經系統疾病、其他）
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 10 章：南美洲基因治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按載體類型（病毒載體、非病毒載體）
    • 依遞送方式（體內、體外）
    • 按適應症（罕見疾病、癌症、神經系統疾病、其他）
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 11 章：中東和非洲基因治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按載體類型（病毒載體、非病毒載體）
    • 依遞送方式（體內、體外）
    • 按適應症（罕見疾病、癌症、神經系統疾病、其他）
    • 按國家/地區
  • MEA：國家分析
    • 南非基因治療
    • 沙烏地阿拉伯基因治療
    • 阿拉伯聯合大公國基因治療

第 12 章：市場動態

  • 促進要素
  • 挑戰

第 13 章：市場趨勢與發展

  • 近期發展
  • 併購
  • 產品發布

第 14 章：全球基因治療市場：SWOT 分析

第 15 章：資金分析

第16章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第17章：競爭格局

  • 商業概覽
  • 產品供應
  • 最近的發展
  • 財務（據報導）
  • 主要人員
  • SWOT分析
    • REGENXBIO Inc.
    • Oxford Biomedica PLC.
    • Voyager Therapeutics Inc.
    • Human Stem Cells Institute
    • Dimension Therapeutics, Inc.
    • Bristol-Myers Squibb Company
    • Sanofi-Aventis
    • Applied genetic technologies corporation.
    • F. Hoffmann-la Roche ltd.
    • Bluebird bio, Inc.
    • Novartis AG
    • Uniqure NV

第 18 章：策略建議

簡介目錄
Product Code: 17109

The Global Gene Therapy Market, valued at USD 6.01 Billion in 2022, is poised for substantial growth in the forecast period, with a projected Compound Annual Growth Rate (CAGR) of 9.26% and is expected to reach USD 10.13 Billion by 2028. Gene therapy involves the treatment of illnesses by modifying, replacing, or supplementing missing or defective genetic combinations responsible for the disease. It has emerged as a highly desirable research frontier in combating degenerative diseases.

The increasing prevalence of cancer and other chronic diseases worldwide is driving the need for gene therapy. Anticipated advancements in gene therapies, expected to receive approvals in the coming years, are set to contribute significantly to the growth of the gene therapy market during the forecast period. Gene therapies are designed to address diseases by altering genetic information, such as deactivating malfunctioning genes or substituting a disease-causing gene with a healthy one. This approach has demonstrated effectiveness in treating a variety of disorders, including diabetes, cancer, heart disease, and AIDS.

Key Market Drivers

Market Overview
Forecast Period2024-2028
Market Size 2022USD 6.01 Billion
Market Size 2028USD 10.13 Billion
CAGR 2023-20289.26%
Fastest Growing SegmentNon-Viral Vectors
Largest MarketNorth America
  • 1. Advancements in Genetic Research: Growing insights into the genetic basis of diseases have empowered scientists to pinpoint specific genes responsible for various disorders. This knowledge is pivotal in developing precise gene therapies that can rectify or replace defective genes, tackling the root causes of diseases. Advancements in gene editing technologies, such as CRISPR-Cas9, TALENs, and zinc finger nucleases, have revolutionized gene therapy by enabling accurate and efficient gene modifications. This, in turn, has opened new avenues for treating genetic disorders.
  • 2. Rising Prevalence of Genetic Disorders: The increasing number of individuals diagnosed with genetic disorders underscores the unmet medical need for effective treatments. Gene therapy offers targeted and long-lasting solutions for these disorders, which are often managed symptomatically rather than at their genetic source. The growing prevalence of genetic disorders expands the potential patient base, driving demand for gene therapy and market opportunities.
  • 3. Collaborations and Partnerships: Gene therapy necessitates a multidisciplinary approach, involving molecular biology, genetics, biotechnology, clinical research, and regulatory affairs. Collaborations facilitate the pooling of knowledge, expertise, and best practices across diverse fields, fostering innovation and expediting the development of more advanced gene therapies. Partnerships grant access to specialized technologies and tools, promoting breakthroughs in gene therapy development. They also aid in the development of scalable manufacturing techniques and provide support in navigating complex regulatory landscapes, ultimately contributing to market growth.

Key Market Challenges

  • 1. Technical Complexity: The development of effective gene therapies requires a profound understanding of genetics, molecular biology, and intricate cellular processes. The complexity of designing therapies that accurately target and modify specific genes can lead to prolonged research and development timelines. Challenges in achieving precise and controlled gene delivery, along with potential unintended consequences, pose technical difficulties, affecting therapy success.
  • 2. High Development Costs: Gene therapy development involves significant initial research, extensive clinical trial costs, regulatory compliance expenses, and the need to build skilled teams. Cutting-edge technologies and sophisticated laboratory equipment also contribute to high development costs. Attracting and retaining experts in the field can be expensive due to its specialized nature.

Key Market Trends

  • 1. Expanding Therapeutic Targets: The identification of new therapeutic targets broadens the scope of gene therapy applications to include complex diseases like cancer, cardiovascular diseases, neurodegenerative disorders, and rare conditions. This diversification attracts a larger patient base, driving market growth by increasing commercial opportunities. It fosters innovation, accelerates research, and results in a more diverse clinical trial landscape.
  • 2. Growing CRISPR-Based Therapies: CRISPR-Cas9 technology's precision in gene editing has accelerated gene therapy research. Its ability to target and modify genes accurately enhances therapy efficacy and safety. CRISPR-based therapies have the potential to address a wide range of genetic disorders, from monogenic to complex conditions, and simplify the regulatory approval process. The accessibility of CRISPR technology has spurred global collaboration, leading to competition, innovation, and market expansion.

Segmental Insights

Vector Type Insights: The Non-Viral Vector segment is expected to witness significant market growth throughout the forecast period. Non-viral vectors offer a safer profile with reduced immune response risks compared to viral vectors. Their lower risk of integrating into the host genome enhances long-term therapeutic applications. Non-viral vectors also simplify manufacturing processes, potentially reducing production costs and enabling scalability. Their safety advantages can lead to smoother regulatory pathways, expediting approvals. The emergence of non-viral vector technologies attracts a diverse range of industry players, promoting competition, innovation, and market expansion.

Delivery Method Insights: The In-Vivo segment has dominated the market due to its non-invasive nature, making it more acceptable to patients and reducing risks associated with surgical procedures. In vivo gene therapy can be administered systemically, making it accessible to a broader range of patients and suitable for conditions affecting multiple organs or tissues. Its systemic effect can be beneficial for diseases with widespread genetic abnormalities, offering long-lasting effects. In vivo gene therapy's versatility attracts a diverse range of researchers, developers, and companies to the gene therapy market.

Regional Insights

North America, specifically the United States, has been the leader in the gene therapy market in 2022. This is attributed to the region's robust research and innovation ecosystem, attracting significant investments from various sources into gene therapy research and clinical trials. North America boasts well-established clinical trial infrastructure, a multitude of biotechnology companies dedicated to gene therapy, and advanced healthcare infrastructure, creating a favorable environment for gene therapy research, clinical application, and adoption.

Key Market Players

  • REGENXBIO Inc.
  • Oxford Biomedica PLC.
  • Voyager Therapeutics Inc.
  • Human Stem Cells Institute
  • Dimension Therapeutics, Inc.
  • Bristol-Myers Squibb Company
  • Sanofi-Aventis
  • Applied genetic technologies corporation.
  • F. Hoffmann-la roche ltd.
  • Bluebird bio, inc.
  • Novartis ag
  • Uniqure n.v

Report Scope:

In this report, the Global Gene Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Gene Therapy Market, By Vector Type:

  • Viral Vector
  • Non-Viral Vector

Gene Therapy Market, By Delivery Method:

  • In-Vivo
  • Ex-Vivo

Gene Therapy Market, By Indication:

  • Rare Diseases
  • Cancer
  • Neurological Diseases
  • Others

Gene Therapy Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Gene Therapy Market.

Available Customizations:

  • Global Gene Therapy market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Clinical Trial Analysis

  • 4.1 Ongoing Clinical Trials
  • 4.2 Completed Clinical Trials
  • 4.3 Terminated Clinical Trials
  • 4.4 Breakdown of Pipeline, By Development Phase
  • 4.5 Breakdown of Pipeline, By Status
  • 4.6 Breakdown of Pipeline, By Study Type
  • 4.7 Breakdown of Pipeline, By Region
  • 4.8 Clinical Trials Heat Map

5. Voice of Customer

6. Global Gene Therapy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
      • 5.2.1.1 By Viral Vectors (Retro Viral Vectors, Adeno-associated Viral Vectors, Others)
      • 5.2.1.2 By Non-Viral Vectors (Oligonucleotides, Others)
    • 6.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
    • 6.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
    • 6.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
    • 6.2.5. By Company (2022)
  • 6.3. Market Map
    • 5.3.1 By Vector Type
    • 5.3.2 By Delivery Method
    • 5.3.3 By Indication
    • 5.3.4 By Region

7. North America Gene Therapy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
      • 7.2.1.1 By Viral Vectors (Retro Viral Vectors, Adeno-associated Viral Vectors, Others)
      • 7.2.1.2 By Non-Viral Vectors (Oligonucleotides, Others)
    • 7.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
    • 7.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Gene Therapy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Vector Type
        • 7.3.1.2.2. By Delivery Method
        • 7.3.1.2.3. By Indication
    • 7.3.2. Canada Gene Therapy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Vector Type
        • 7.3.2.2.2. By Delivery Method
        • 7.3.2.2.3. By Indication
    • 7.3.3. Mexico Gene Therapy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Vector Type
        • 7.3.3.2.2. By Delivery Method
        • 7.3.3.2.3. By Indication

8. Europe Gene Therapy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
      • 8.2.1.1 By Viral Vectors (Retro Viral Vectors, Adeno-associated Viral Vectors, Others)
      • 8.2.1.2 By Non-Viral Vectors (Oligonucleotides, Others)
    • 8.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
    • 8.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
    • 8.2.4. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Gene Therapy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Vector Type
        • 8.3.1.2.2. By Delivery Method
        • 8.3.1.2.3. By Indication
    • 8.3.2. Germany Gene Therapy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Vector Type
        • 8.3.2.2.2. By Delivery Method
        • 8.3.2.2.3. By Indication
    • 8.3.3. United Kingdom Gene Therapy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Vector Type
        • 8.3.3.2.2. By Delivery Method
        • 8.3.3.2.3. By Indication
    • 8.3.4. Italy Gene Therapy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Vector Type
        • 8.3.4.2.2. By Delivery Method
        • 8.3.4.2.3. By Indication
    • 8.3.5. Spain Gene Therapy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Vector Type
        • 8.3.5.2.2. By Delivery Method
        • 8.3.5.2.3. By Indication

9. Asia-Pacific Gene Therapy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
      • 9.2.1.1 By Viral Vectors (Retro Viral Vectors, Adeno-associated Viral Vectors, Others)
      • 9.2.1.2 By Non-Viral Vectors (Oligonucleotides, Others)
    • 9.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
    • 9.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
    • 9.2.4. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Gene Therapy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Vector Type
        • 9.3.1.2.2. By Delivery Method
        • 9.3.1.2.3. By Indication
    • 9.3.2. India Gene Therapy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Vector Type
        • 9.3.2.2.2. By Delivery Method
        • 9.3.2.2.3. By Indication
    • 9.3.3. Japan Gene Therapy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Vector Type
        • 9.3.3.2.2. By Delivery Method
        • 9.3.3.2.3. By Indication
    • 9.3.4. South Korea Gene Therapy Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Vector Type
        • 9.3.4.2.2. By Delivery Method
        • 9.3.4.2.3. By Indication
    • 9.3.5. Australia Gene Therapy Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Vector Type
        • 9.3.5.2.2. By Delivery Method
        • 9.3.5.2.3. By Indication

10. South America Gene Therapy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
      • 10.2.1.1 By Viral Vectors (Retro Viral Vectors, Adeno-associated Viral Vectors, Others)
      • 10.2.1.2 By Non-Viral Vectors (Oligonucleotides, Others)
    • 10.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
    • 10.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Gene Therapy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Vector Type
        • 10.3.1.2.2. By Delivery Method
        • 10.3.1.2.3. By Indication
    • 10.3.2. Argentina Gene Therapy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Vector Type
        • 10.3.2.2.2. By Delivery Method
        • 10.3.2.2.3. By Indication
    • 10.3.3. Colombia Gene Therapy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Vector Type
        • 10.3.3.2.2. By Delivery Method
        • 10.3.3.2.3. By Indication

11. Middle East and Africa Gene Therapy Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
      • 11.2.1.1 By Viral Vectors (Retro Viral Vectors, Adeno-associated Viral Vectors, Others)
      • 11.2.1.2 By Non-Viral Vectors (Oligonucleotides, Others)
    • 11.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
    • 11.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
    • 11.2.4. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Gene Therapy Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Vector Type
        • 11.3.1.2.2. By Delivery Method
        • 11.3.1.2.3. By Indication
    • 11.3.2. Saudi Arabia Gene Therapy Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Vector Type
        • 11.3.2.2.2. By Delivery Method
        • 11.3.2.2.3. By Indication
    • 11.3.3. UAE Gene Therapy Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Vector Type
        • 11.3.3.2.2. By Delivery Method
        • 11.3.3.2.3. By Indication

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Development
  • 13.2. Mergers & Acquisitions
  • 13.3. Product Launches

14. Global Gene Therapy Market: SWOT Analysis

15. Funding Analysis

16. Porter's Five Forces Analysis

  • 16.1. Competition in the Industry
  • 16.2. Potential of New Entrants
  • 16.3. Power of Suppliers
  • 16.4. Power of Customers
  • 16.5. Threat of Substitute Products

17. Competitive Landscape

  • 17.1. Business Overview
  • 17.2. Product Offerings
  • 17.3. Recent Developments
  • 17.4. Financials (As Reported)
  • 17.5. Key Personnel
  • 17.6. SWOT Analysis
    • 15.6.1 REGENXBIO Inc.
    • 15.6.2 Oxford Biomedica PLC.
    • 15.6.3 Voyager Therapeutics Inc.
    • 15.6.4 Human Stem Cells Institute
    • 15.6.5 Dimension Therapeutics, Inc.
    • 15.6.6 Bristol-Myers Squibb Company
    • 15.6.7 Sanofi-Aventis
    • 15.6.8 Applied genetic technologies corporation.
    • 15.6.9 F. Hoffmann-la Roche ltd.
    • 15.6.10 Bluebird bio, Inc.
    • 15.6.11 Novartis AG
    • 15.6.12 Uniqure N.V.

18. Strategic Recommendations